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Abstract
Although severe prolongation of activated partial thromboplastin time is observed in patients with
plasma prekallikrein（PKK）deficiency, clinical bleeding is not seen. Instead, the possibility that
impaired fibrinolysis contributes to thrombosis, myocardial infarction and cerebral thrombosis has been
postulated. We report a case of cross-reacting material-negative plasma PKK deficiency associated
with thrombophlebitis of the lower extremities. This patient developed progressively deteriorating
drug-induced liver injury and showed a state of acute liver failure. The patient also had intractable
gastric ulcer with a history of repeated recurrence. Microcirculatory disorder associated with a
reduction in fibrinolytic activity appeared to be involved in the deterioration of liver injury and also in
the process of the gastric ulcer becoming intractable.
Introduction
In 1965, Hathaway et al1）. discovered a
family with an autosomal-recessive hereditary
disease characterized by prolonged activated
partial thromboplastin time（APTT）without
bleeding tendency, and called this pathology
“Fletcher factor deficiency”. Wuepper later
reported that the Fletcher factor was plasma
prekallikrein（PKK）2）. PKK deficiency is a
very rare disease, with only a few cases
reported to date3）～13）. Myocardial infarction5）
and cerebral thrombosis10） have been reported
as complications, and several reports14）～16）have
described plasma PKK as required for the
expression of a plasminogen activator. In this
paper, we report a case of cross-reacting
material-negative（CRM-） plasma PKK defi-
ciency associated with acute liver failure, in-
tractable gastric ulcer and thrombophlebitis of
the lower extremities.
Case report
Patient
The patient was a 44-year-old Japanese
woman without any family history of consanguin-
ity. The first hospital admission in January1980
was for gastric ulcer. After discharge, she expe-
rienced repeated exacerbations of gastric ulcer
（Fig. 1）. No evidence of abnormal liver function
was seen. Beginning around November1982, the
patient noted the onset of appetite loss, nausea
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and vomiting. After undergoing treatment with
400mg／day of cimetidine, the patient developed
jaundice followed by hepatic encephalopathy, and
was admitted to our hospital for a second time in
December1982. The results of laboratory tests
performed at the time of admission were : total
bilirubin,19．0mg／dl （normal,0．1-1．1mg／dl）;
direct bilirubin,17．0mg／dl（normal,0．1-0．6mg／
dl）; prothrombin time（PT）,40％（normal,80-
125％）; APTT,45．3sec（normal,21．5-43．1sec）.
Taking these liver function test results into
account, the prolonged PT and APTT appeared
to attributable to liver injury, with no apparent
clotting factor deficiencies or clotting factor inhibi-
tors. All virus markers were negative, including
immunoglobulin（Ig）M-Hepatitis B core antibody,
IgM-Hepatitis A antibody, and Hepatitis C Virus
antibody. The cimetidine lymphoblast transfor-
mation reaction was negative, but a subsequent
challenge test yielded positive results, indicating
the presence of cimetidine-induced liver injury.
After admission, hepatic encephalopathy im-
proved in response to conservative systemic man-
agement including intravenous hyper-alimentation,
administration of fresh frozen plasma, etc. A
gradual improvement in liver function was also
observed. While serum bilirubin decreased and
PT gradually normalized, APTT contrarily be-
came longer. At the time PT became normal,
APTT was between 70 and 80 sec（Fig. 2）.
Liver biopsy performed during the third month of
hospitalization revealed bridging necrosis, with
massive lobular necrosis in one portion（Fig. 3）.
The patient was subsequently followed-up as an
outpatient, but the prolonged APTT persisted.
Onset of epigastralgia was noted around Septem-
ber 1990, and because of exacerbation of the
gastric ulcer and accompanying thrombophlebitis
of the lower extremities（Fig. 4）, the patient was
admitted for a third time in February1991. The
following laboratory examinations were performed
during this admission.
Fig. 1 Endoscopic findings of gastric ulcer situated
on the posterior wall of the body of the
stomach. The ulcer was intractable and
repeated recurrence had been seen through-
out10years in almost the same place.
Fig. 2 Clinical course. The patient developed acute
liver failure in November1982. Serum AST
concentration showed a biphasic elevation.
While serum bilirubin decreased and PT
gradually normalized, APTT contrarily be-
came longer.
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Materials and methods
Venous blood was collected from a cubital
vein and immediately mixed with 0．109mol／l
trisodium citrate（9：1, v／v）. Platelet-poor plasma
was obtained by centrifuging the blood at 4℃ for
20 min at 3，000g . Coagulation tests were per-
formed using fresh plasma. Plasma for immu-
nological studies was stored frozen at －80℃.
Normal plasma was obtained from 20 healthy
doctors by the same method. PKK-deficient
plasma and high-molecular weight （HMW）
kininogen-deficient plasma were purchased from
George King Bio-Medical（Overland park, KS）.
Anti-PKK goat serum was purchased from Nordic
Immunological Laboratories（Susteren, the Neth-
erlands）. Chromozyme PK （BZ-Pro-Phe-Arg-
pNA ） was purchased from Boehringer
（Mannheim, Germany）. The activity of Factors
II, V, VII, VIII, IX, X, XI and XII was measured
with commercially available one-stage assays
using plasma that was deficient in each factor.
PKK activity was measured by one-stage assay
using PKK-deficient plasma and by chromogenic
peptide substrate assay17）. We measured PKK
antigen concentration by Laurel rocket immuno-
electrophoresis18）. The activity of HMW kinino-
gen was measured by a one-stage assay using
HMW kininogen-deficient plasma19）.
Clinical course and results of laboratory examination
At the time of the third admission, PT was
within normal limits, but APTT was found to be
prolonged. No particular abnormalities were de-
tected in levels of any clotting factors. Results of
quantitative determination of HMW kininogen and
PKK activity by one-stage assay using plasma
deficient in each of them showed HMW kininogen
to be within normal limits, but PKK level was
markedly reduced, and a PK deficiency was there-
fore diagnosed（Table1）. During the second
admission, while serum bilirubin decreased and
Fig. 3 Photomicrogram of the liver specimen.
Bridging fibrosis and an enlarged portal tract
with inflammatory reaction are noted. Mas-
sive lobular necrosis is also noted in one
portion.
Fig. 4 Thrombophlebitis in the lower extremities.
Table 1 Results from coagulation tests of the patient
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PT gradually normalized, APTT contrarily be-
came longer （Fig. 2）. This phenomenon sug-
gested that while clotting factor production had
recovered as a result of liver cell regeneration,
and PT had become normal, the regenerated liver
cells might have lost their ability to produce PKK.
Accordingly, we thought that we should evaluate
any changes in serum PKK activity before the
patient developed acute liver failure. Fortunately,
we had stored samples of serum from the patient
at －80℃ when she was hospitalized the first time
in January 1980, and we were thus able to
determine PKK antigen levels as of that time
（Fig. 5）. The serum antigen level in January
1980was51％ ; this was low, but still far higher
than the 1％ in plasma as of February 1991.
Worsening of PKK deficiency in this patient
seemed very likely to be triggered by the
development of acute liver failure. To determine
whether a genetic element was involved in the
etiology, we determined PKK activity and antigen
levels in blood relatives of the present patient
（ Fig. 6 ; Table2）. Her daughter, grandchild
and niece all showed slightly reduced levels of
PKK, suggesting these individuals were heterozy-
gotes.
Discussion
Plasma PKK values decrease in patients with
liver disease, and the etiology is believed to
involve diminished PKK synthesis in the liver20）
and endotoxemia21）. The patient presented in this
paper showed completely normal results from
liver function tests when admitted to hospital for a
third time（when the decrease in plasma PKK
was detected）. No liver injury was suggested
from other clotting factors or results of blood
coagulation tests. The decrease in plasma PKK
thus did not seem attributable to the direct effects
of decreased liver function.
There are two very interesting observations
regarding the association between PKK deficiency
and other associated diseases in this patient. The
first point is that the worsening seemed very
likely if PKK deficiency in this patient was
triggered by the development of acute liver
failure. Hepatic PKK production decreased as
Table 2 PKK values of family members
Fig. 5 Rocket immunoelectrophoresis studies of PKK
in plasma from the patient. 1）Normal
plasma ;2）diluted normal plasma（1／2）;3）
diluted normal plasma（1／4）;4）diluted normal
plasma（1／8）;5,6）plasma from the patient
（February 1991）;7,8）serum from the
patient（January1980）.
Fig. 6 Family tree.
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liver regenerated ; in other words, the decrease in
PKK production was due to changes in the nature
of the regenerated hepatocytes. PKK antigen
levels were very low, meaning that generation of
an inhibitor against PKK unlikely. Because the
patient had relatives who were heterozygotes,
this patient could have been a hetero- or homo-
zygote with a defective PKK gene. As a result,
whether this represents aggravation by acute
liver failure in a heterozygote or a homozygote
manifesting the disease as a result of triggering
by acute liver failure remains obscure.
The second point is that the PKK deficiency
may have contributed to the increasing severity of
the liver injury and to the intractable nature of
the gastric ulcer. Plasma PKK（along with HMW
kininogen, Factor XI and Factor XII）is referred
to as a contact factor, and not only participates in
intrinsic systemic clotting, but is known to be
intimately involved in processes such as extrinsic
systemic clotting, the fibrinolytic system, kinin
production, and complement activation22）. Plasma
PKK is activated to kallikrein by activated Factor
XII, and this kallikrein then activates HMW kini-
nogen to kinin and converts Factor XI to acti-
vated Factor XI, thereby activating the clotting
system. Kallikrein also activates the fibrinolytic
system by converting plasminogen into plasmin23）.
Clinically, while no bleeding tendency has been
observed in PKK deficiency, thrombosis has been
reported instead5），10），14）～16）. On the other hand,
impaired circulation in the gastric mucosa has
been cited as one of the pathogenetic mechanisms
underlying gastric ulcer24）, and impaired micro-
circulation in the liver is regarded as a factor
adversely affecting liver function in acute liver
failure25），26）. The decrease in fibrinolytic activity
appears highly likely to further impair the micro-
circulation through the liver sinusoids and gastric
mucosal blood flow in this case, and the liver
damage and condition of the gastric ulcer would
thus have become more severe.
PKK deficiency is not thought to have con-
tributed to the initiation of liver damage or gastric
ulcer, but it seems reasonable to assume that this
deficiency was involved in both becoming more
severe and intractable. When we consider the
mechanisms underlying the development of acute
liver failure and by which the gastric ulcer
became more severe, the existence of patient-
specific background factors such as abnormalities
of the coagulation／ fibrinolytic system and
thrombogenesis-promoting factors, along with en-
suing microcirculatory impairment, must always
kept in mind.
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急性肝不全と難治性胃潰瘍を合併したプレカリクレイン欠乏症の一例
上甲 康二*，羽藤 高明**
*松山赤十字病院 肝胆膵センター
**愛媛県赤十字血液センター
プレカリクレイン（PKK）欠乏症においては活性化部分トロンボプラスチン時間が延長するにも
かかわらず出血傾向は見られないが，繊維素溶解が障害されることにより血栓症，心筋梗塞や脳梗
塞を発症する可能性が指摘されている．著者らは下肢血栓性静脈炎を伴う先 PKK欠乏症の一例を経
験した．この症例は以前より再発を繰り返す難治性胃潰瘍があり，また経過観察中に薬物性肝障害
が重症化し急性肝不全を呈した．繊維素溶解障害が微小循環障害を引き起こすことにより，胃潰瘍
の難治性化や肝障害の重症化に関与した可能性があり，疾病重症化の機序を考える上で興味ある症
例と思われたので報告した．
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